1. Background
2. Objectives
3. Methods
3.1. Isolation of Staphylococcus aureus and Phenotypic Confirmation of Isolates
3.2. Molecular Confirmation of Staphylococcus aureus Isolates
3.3. Identification of Methicillin-resistant Staphylococcus aureus Isolates
3.4. Examining Antibiotic Sensitivity Patterns
3.5. Detection of SCCmec and ccr Typing with Multiplex Polymerase Chain Reaction
3.6. Prophage Typing
3.7. Investigating the Presence of Important Toxins of Methicillin-resistant Staphylococcus aureus
3.8. Evaluation of Polymerase Chain Reaction Products
3.9. Statistical Analysis
4. Results
4.1. Staphylococcus aureus Isolates Phenotypic and Molecular Confirmation
4.2. Identification of Methicillin-resistant Staphylococcus aureus Isolates
(A) PCR amplification products of nuc genes run on the agarose gel. The negative control is in lane 1, followed by the positive nuc samples in lanes 2, 3, and 4, the positive control in lane 5, and the 100-bp DNA molecular weight marker in lane 6. (B) Analysis of PCR products by agarose gel electrophoresis of mecA genes. Lane 1: 100-bp DNA molecular weight marker, followed by positive control in lane 2, positive mecA sample (310 bp) in lanes 3 - 5, and negative control in lane 6. (C) Agarose gel electrophoresis of multiplex PCR products of SCCmec genes. Lanes 1 and 2: SCCmec type IV (415 and 937 bp); lanes 4, 5, and 6: SCCmec type III (518 bp); lanes 8 and 9: SCCmec type I (415 bp); lanes 3, 7, and 10: negative control; lane 11: 100-bp DNA molecular weight marker.
| Antimicrobial Drug | Source of MRSA, No. (%) | Total, No. (%) | P Value | |
|---|---|---|---|---|
| HA | CA | |||
| Penicillin | 50 (100) | 12 (100) | 62 (100) | 1.000 |
| Ciprofloxacin | 38 (76) | 6 (50) | 44 (71) | 0.075 |
| Erythromycin | 38 (76) | 4 (33) | 42 (68) | 0.005 a |
| Tetracycline | 31 (62) | 8 (67) | 39 (63) | 0.764 |
| Amikacin | 33 (66) | 5 (42) | 38 (61) | 0.120 |
| Tobramycin | 32 (64) | 5 (42) | 37 (60) | 0.157 |
| Kanamycin | 33 (66) | 3 (25) | 36 (58) | 0.010 b |
| Clindamycin | 33 (66) | 2 (17) | 35 (56) | 0.002 a |
| Gentamicin | 22 (44) | 2 (17) | 24 (39) | 0.081 |
| Chloramphenicol | 2 (4) | 0 | 2 (3) | 0.481 |
Abbreviations: HA, hospital-acquired; CA, community-acquired.
a P < 0.01
b P < 0.05
4.3. Patterns of Antibiotic-resistant Methicillin-resistant Staphylococcus aureus Isolates
| Sample | SCCmec I | SCCmec III | SCCmec IV | pvl | SGA Prophage | Total |
|---|---|---|---|---|---|---|
| Urine | 0 | 6 (21.4) | 0 | 0 | 0 | 6 (9.7) |
| Wound | 13 (59.1) | 9 (32.1) | 4 (33.3) | 4 (33.3) | 4 (33.3) | 26 (41.9) |
| Blood | 4 (18.2) | 3 (10.7) | 3 (25) | 3 (25) | 3 (25) | 10 (16.1) |
| Synovial fluid | 0 | 1 (3.6) | 2 (16.6) | 2 (16.6) | 2 (16.6) | 3 (4.8) |
| Respiratory system | 2 (9.1) | 8 (28.6) | 1 (8.3) | 1 (8.3) | 1 (8.3) | 11 (17.7) |
| Abscess | 2 (9.1) | 1 (3.6) | 0 | 0 | 0 | 3 (4.8) |
| Secretion | 1 (4.5) | 0 | 2 (16.6) | 2 (16.6) | 2 (16.6) | 3 (4.8) |
| P Value | 0.014 b | 0.052 | 0.096 | |||
a Values are presented as No. (%).
b P < 0.05
4.4. Characterization of Methicillin-resistant Staphylococcus aureus Isolates by SCCmec and ccr Typing
| Number of Resistant Antibiotics | Number of Microorganisms (MRSA) | Sccmec Type | Number of Patterns |
|---|---|---|---|
| 1 | 3 | 2 isolates Sccmec type I, 1 isolates Sccmec type IV | 1 |
| 2 | 3 | 1 isolates Sccmec type I, 2 isolates Sccmec type IV | 2 |
| 3 | 5 | 2 isolates Sccmec type I, 3 isolates Sccmec type IV | 4 |
| 4 | 9 | 5 isolates Sccmec type I, 2 isolates Sccmec type III, 2 isolates Sccmec type IV | 6 |
| 5 | 7 | 1 isolates Sccmec type I, 4 isolates Sccmec type III, 2 isolates Sccmec type IV | 7 |
| 6 | 11 | 6 isolates Sccmec type I, 5 isolates Sccmec type III | 11 |
| 7 | 4 | 2 isolates Sccmec type I, 1 isolates Sccmec type III, 1 isolates Sccmec type IV | 4 |
| 8 | 10 | 2 isolates Sccmec type I, 7 isolates Sccmec type III, 1 isolates Sccmec type IV | 4 |
| 9 | 10 | 1 isolates Sccmec type I, 9 isolates Sccmec type III | 1 |
| P value | 0.003 a |
a P < 0.01
4.5. Prophage Typing
| Phage Pattern | Phage Type | Number of MRSA Isolates, No. (%) | ||||
|---|---|---|---|---|---|---|
| SGA | SGB | SGF | SGFa | SGFb | ||
| 1 | - | + | + | + | + | 23 (37.10) |
| 2 | - | - | + | + | + | 20 (32.26) |
| 3 | + | + | + | + | + | 8 (12.90) |
| 4 | + | - | + | + | + | 4 (6.45) |
| 5 | - | - | + | - | + | 3 (4.83) |
| 6 | - | + | + | - | + | 2 (3.22) |
| 7 | - | + | + | - | - | 2 (3.22) |
| Total, No. (%) | 12 (19.35) | 35 (56.45) | 62 (100) | 55 (88.71) | 60 (96.77) | 62 (100) |
Analysis of PCR products by agarose gel electrophoresis of prophage typing. A: (SGF prophage); Lane 1: 100-bp DNA molecular weight marker, followed by positive control in lane 2, positive SGF sample (155 bp) in lanes 3 and 4, and negative control in lane 5. B: (SGFa); Lane 1: 100-bp DNA molecular weight marker, followed by negative control in lane 2, positive SGF sample (548 bp) in lanes 3 - 5, and positive control in lane 6. C: (SGFb); Lane 1: 100-bp DNA molecular weight marker, followed by positive control in lane 2, positive SGFba sample (147 bp) in lanes 3 - 5, and negative control in lane 6. D: (SGA); Lane 1: 100-bp DNA molecular weight marker, followed by negative control in lane 2, positive SGA sample (744 bp) in lanes 3-6, and positive control in lane 7. E: (SGB prophage); Lane 1: 100-bp DNA molecular weight marker, followed by positive control in lane 2, positive SGB sample (405 bp) in lanes 3 - 6, and negative control in lane 7.
4.6. Identification of Toxin Genes in Methicillin-resistant Staphylococcus aureus Isolates
Analysis of PCR products by agarose gel electrophoresis of toxin genes: (A) pvl genes (433 bp), (B) hlb genes (525bp), (C) sak genes (383bp), (D) tst genes (350bp); (E) eta genes(119bp). Lane 1: 100-bp DNA molecular weight marker; lanes 2, 3, and 4: Positive samples; lane 5: Positive control; lane 6: Negative control.
| Pattern | Patterns of Toxins | No. (%) | |||||
|---|---|---|---|---|---|---|---|
| sak | hlb | tst | pvl | eta | etb | ||
| 1 | + | - | - | - | + | - | 12 (19.35) |
| 2 | + | - | - | - | - | - | 9 (14.51) |
| 3 | + | + | - | - | + | - | 7 (11.29) |
| 4 | + | - | - | + | + | - | 6 (9.67) |
| 5 | + | + | - | - | - | - | 5 (8.06) |
| 6 | - | + | - | - | + | - | 5 (8.06) |
| 7 | - | + | - | - | - | - | 3 (4.83) |
| 8 | + | + | - | + | + | - | 2 (3.22) |
| 9 | - | + | - | + | - | - | 2 (3.22) |
| 10 | - | - | - | - | + | - | 2 (3.22) |
| 11 | + | + | - | + | - | - | 1 (1.61) |
| 12 | + | - | - | + | - | - | 1 (1.61) |
| 13 | + | - | + | - | + | - | 1 (1.61) |
| 14 | - | + | + | - | - | - | 1 (1.61) |
| 15 | - | - | - | - | - | - | 5 (8.06) |
| Total, No. (%) | 44 (70.96) | 26 (41.93) | 2 (3.22) | 12 (19.35) | 35 (56.45) | 0 | 62 (100) |


